IgA肾病患者糖皮质激素治疗相关严重不良事件分析
该研究基于2003至2014年单中心1034例IgA肾病患者队列,发现接受激素治疗者严重不良事件发生率为12.5%,显著高于未用激素者的2.7%(OR 5.45)。高龄和高血压是激素相关严重不良事件的危险因素,肾功能受损是严重感染的危险因素,累积激素剂量未显示与严重不良事件相关。
要点
- IgA肾病患者使用激素者严重不良事件风险显著升高(OR 5.45)。
- 高龄和高血压是激素相关严重不良事件的独立危险因素。
- 肾功能受损增加激素治疗中严重感染的风险。
核心结论
- IgA肾病患者使用糖皮质激素与严重不良事件高风险相关,尤其在高龄、高血压或肾功能受损者中。
研究设计与样本
- 单中心回顾性队列研究,纳入2003至2014年随访的1034例IgA肾病患者,其中369例接受激素治疗。
主要发现
- 激素治疗组46例(12.5%)发生58次严重不良事件,未用激素组18例(2.7%)发生严重不良事件(OR 5.45;95%CI 3.07-9.68;P<0.001)。
- 严重不良事件包括糖尿病19例(5.1%)、严重或致命感染18例(4.9%)、股骨头坏死或骨折6例(1.6%)、心脑血管病4例(1.1%)、白内障3例(0.8%)、消化道出血1例(0.3%)。
- 多因素分析显示高龄(OR 1.05;95%CI 1.02-1.07;P<0.001)和高血压(OR 1.04;95%CI 1.01-1.06;P=0.009)是激素相关严重不良事件的危险因素。
- 累积激素剂量未显示与严重不良事件相关(OR 1.09;95%CI 0.91-1.30;P=0.365)。
临床怎么用
- 对IgA肾病患者启用激素前应评估高龄、高血压和肾功能,权衡获益与严重不良事件风险。
- 激素治疗期间需重点监测感染、血糖、骨骼及心血管事件。
局限性
- 单中心回顾性设计,可能存在选择偏倚和未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Few data are available on the risk of SAEs in corticosteroid users in IgAN populations. We describe the prevalence and risk factors of corticosteroid-related SAEs in a Chinese cohort. METHODS: A total of 1034 IgAN patients were followed up in our renal center from 2003 to 2014. Prevalence of corticosteroid use and corticosteroid-related SAEs were noted. Logistic regression was used to search for risk factors of SAEs in corticosteroid users. RESULTS: Of the 369 patients with steroids therapy, 46 patients (12.5%) with 58 events suffered SAEs, whereas only 18 patients (2.7%) without corticosteroids suffered SAEs (OR: 5.45; 95% CI: 3.07-9.68; P < 0.001). SAEs included diabetes mellitus (n = 19, 5.1%), severe or fatal infection (n = 18, 4.9%), osteonecrosis of the femoral head or bone fracture (n = 6, 1.6%), cardiocerebral vascular disease (n = 4, 1.1%), cataract (n = 3, 0.8%), and gastrointestinal hemorrhage (n = 1, 0.3%). Multivariable logistic regression analysis revealed that advanced age (OR: 1.05; 95% CI: 1.02-1.07; P < 0.001) and hypertension (OR: 1.04; 95% CI: 1.01-1.06; P = 0.009) were risk factors for corticosteroid-related SAEs. Impaired kidney function (estimated GFR: OR: O.98; 95% CI: 0.96-0.99; P = 0.036) was a risk factor for severe infection. Accumulated dosages of corticosteroids were not identified as a risk factor of SAEs (OR: 1.09; 95% CI: 0.91-1.30; P = 0.365). DISCUSSION: Corticosteroid use is associated with a high risk of SAEs in IgAN patients, especially those who are older, have hypertension, or impaired renal function. Current guidelines on corticosteroid regimens in IgAN should be reviewed with regard to safety.
引用
- Cai Q, Xie X, Wang J, et al. Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy. Kidney Int Rep. 2017. PMID: 29142978. doi:10.1016/j.ekir.2017.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。